We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Aze7.5
Azelaic Acid Research
Mostly mechanism / observationalModerate safety
7 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Azelaic Acid studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality randomised trials published 1989–2023 with a typical study size of 251 participants.
Based on 7 studies · 4 RCTs · 1,285 total participants
Confidence
Moderate
By outcome
Skin tone & pigmentationMeaningful reduction in melasma and post-inflammatory hyperpigmentation (strongest at prescription strength) · 8-24 weeks
Mostly mechanism / observational3 studies
Safety profile
Too few graded studies2 studies
Skin healthReduced inflammatory and comedonal acne lesions (strongest at prescription strength) · 4-12 weeks · Clearer, calmer, more even complexion (reduced redness and blemishes); a dermatologic, not a hydration, effect · 8-15 weeks
Too few graded studies1 study
Steady research
1 study in the last 5 years
198920062023
1RCTn=664 · large study2003
Both studies consistently demonstrated the superiority of AzA gel over vehicle in the topical treatment of moderate, papulopustular rosacea.
Thiboutot D, Thieroff-Ekerdt R, Graupe K. · J Am Acad Dermatol (2003)
Two double-blind, vehicle-controlled phase III RCTs (664 patients total) of 15% azelaic acid gel twice daily for moderate papulopustular rosacea
AzA gel produced significantly greater reductions in inflammatory lesion count than vehicle (58% vs 40%, P=.0001; 51% vs 39%, P=.0208)
Therapeutic success reached 61% and 62% with AzA vs 40% and 48% with vehicle; no serious treatment-related adverse events
There was high quality evidence to support the effectiveness of topical azelaic acid, topical ivermectin, brimonidine, doxycycline and isotretinoin for rosacea.
van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MM, Charland L. · Cochrane Database Syst Rev (2015)
Cochrane review of 106 RCTs (13,631 participants) of rosacea treatments with GRADE quality assessment
Azelaic acid was more effective than placebo for papulopustular rosacea, rated HIGH-quality evidence (participant-assessed RR 1.46, 95% CI 1.30 to 1.63)
Trials comparing azelaic acid head-to-head with metronidazole gave contradictory results on which is superior
Use of 15% azelaic acid gel twice daily for 15 weeks demonstrated significant superiority over using 0.75% metronidazole gel in improving principal signs of rosacea.
Elewski BE, Fleischer AB Jr, Pariser DM. · Arch Dermatol (2003)
Multicenter, double-blind, randomized head-to-head trial in 251 patients with moderate papulopustular rosacea over 15 weeks
Azelaic acid beat metronidazole on inflammatory-lesion reduction (-72.7% vs -55.8%, P<.001) and erythema improvement (56% vs 42%, P=.02)
Neither treatment improved telangiectasia; both were well tolerated with no serious adverse events
BPO + CLN demonstrated greater efficacy than AzA in the treatment of mild-to-moderate acne vulgaris and has a positive tolerability and safety profile.
Schaller M, Sebastian M, Ress C, Seidel D, Hennig M. · J Eur Acad Dermatol Venereol (2016)
Randomized assessor-blinded head-to-head trial (215 patients) of benzoyl peroxide 3%/clindamycin 1% vs azelaic acid 20% over 12 weeks
Azelaic acid did reduce lesions (inflammatory -65.3%, total -53.9%) but was significantly less effective than BPO+clindamycin (-78.8%, -69.0%; P<0.0001)
Azelaic acid caused more application-site reactions (35.8% of patients) than BPO+clindamycin (15.7%) — the key acne counter-evidence
Azelaic acid (20%) was significantly more effective than 2% hydroquinone but not when compared to 4% hydroquinone.
Rajaratnam R, Halpern J, Salim A, Emmett C. · Cochrane Database Syst Rev (2010)
Cochrane review of 20 RCTs (2125 participants) covering 23 melasma treatments; pooling limited by heterogeneity
Azelaic acid 20% beat 2% hydroquinone (RR 1.25, 95% CI 1.06 to 1.48) but showed NO significant advantage over 4% hydroquinone (RR 1.11, 95% CI 0.94 to 1.32)
Authors concluded the overall quality of melasma trials was generally poor — a key limit on the depigmenting claim
AZA is an inhibitor of tyrosinase, mitochondrial respiratory chain enzymes and DNA synthesis, and is a scavenger of harmful free radicals and inhibits the production of reactive oxygen species by neutrophils.
Sauer N, Oślizło M, Brzostek M, Wolska J, Lubaszka K, Karłowicz-Bodalska K. · Postepy Dermatol Alergol (2023)
Reviews azelaic acid's mechanisms: anti-inflammatory, antioxidant, and antimicrobial activity against Cutibacterium acnes
Tyrosinase inhibition plus a selective effect on hyperactive melanocytes underlies its use in melasma and post-inflammatory hyperpigmentation
Commercial topical formulations contain 5% to 20% azelaic acid (cosmetic and drug status); topical use is well tolerated with mild, transient local irritation